Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2022 Filed Jan 20, 2022 22:54 UTC |
Picchio GastonChief Development Officer
|
GrantStock Option (Right to Buy) · Derivative | 256,500 | $2.81 Strike: $2.81 | $720,765.00 |
DisclosureSEC source: 0001447028-22-000008 · wf-form4_164271923431244.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,500 Underlying: Common Shares · 256,500 shares Expires 2032-01-20 F1 · derivative.exercise_date: These stock options will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| January 20, 2022 Filed Jan 20, 2022 22:53 UTC |
McElhaugh Michael J.Chief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 325,850 | $2.81 Strike: $2.81 | $915,638.50 |
DisclosureSEC source: 0001447028-22-000007 · wf-form4_164271921610822.xml · derivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,850 Underlying: Common Shares · 325,850 shares Expires 2032-01-20 F1 · derivative.exercise_date: These stock options will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:02 UTC |
Sofia Michael J.Chief Scientific Officer
|
SaleCommon Shares | 200,000 | $5.09 | $1,018,000.00 |
DisclosureSEC source: 0001447028-21-000068 · wf-form4_163856535580377.xml · nonDerivative · entry 1 Sofia Michael J. · CIK 0001635324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,303,403 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2021. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 11:22 UTC |
Tran TramDirector
|
GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001447028-21-000064 · wf-form4_163671611466902.xml · derivative · entry 1 Tran Tram · CIK 0001892918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Shares · 44,000 shares Expires 2031-11-09 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on November 9, 2021, the date of the grant. F2 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning one year from the grant date. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 21:14 UTC |
Roivant Sciences Ltd.10% owner
|
ConversionSeries A participating convertible preferred shares · Derivative | 1,164,000 | Not disclosed Strike: $7.13 | Not disclosed |
DisclosureSEC source: 0000950103-21-016172 · dp160070_4-rsltd.xml · derivative · entry 2 Roivant Sciences Ltd. · CIK 0001635088 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,164,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On October 18, 2021, 1,164,000 Series A participating convertible preferred shares of the Issuer held by the Reporting Person, which were previously acquired by the Reporting Person in two tranches in October 2017 and January 2018, mandatorily converted into 22,833,922 common shares, without par value (the "Common Shares"), of the Issuer, in accordance with their terms. F1 · derivative.exercise_date: On October 18, 2021, 1,164,000 Series A participating convertible preferred shares of the Issuer held by the Reporting Person, which were previously acquired by the Reporting Person in two tranches in October 2017 and January 2018, mandatorily converted into 22,833,922 common shares, without par value (the "Common Shares"), of the Issuer, in accordance with their terms. F1 · derivative.expiration_date: On October 18, 2021, 1,164,000 Series A participating convertible preferred shares of the Issuer held by the Reporting Person, which were previously acquired by the Reporting Person in two tranches in October 2017 and January 2018, mandatorily converted into 22,833,922 common shares, without par value (the "Common Shares"), of the Issuer, in accordance with their terms. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 21:14 UTC |
Roivant Sciences Ltd.10% owner
|
ConversionCommon shares, without par value | 22,833,922 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-21-016172 · dp160070_4-rsltd.xml · nonDerivative · entry 1 Roivant Sciences Ltd. · CIK 0001635088 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,847,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 18, 2021, 1,164,000 Series A participating convertible preferred shares of the Issuer held by the Reporting Person, which were previously acquired by the Reporting Person in two tranches in October 2017 and January 2018, mandatorily converted into 22,833,922 common shares, without par value (the "Common Shares"), of the Issuer, in accordance with their terms. F1 · price: On October 18, 2021, 1,164,000 Series A participating convertible preferred shares of the Issuer held by the Reporting Person, which were previously acquired by the Reporting Person in two tranches in October 2017 and January 2018, mandatorily converted into 22,833,922 common shares, without par value (the "Common Shares"), of the Issuer, in accordance with their terms. F2 · balance_after: Includes 16,013,540 Common Shares that were previously acquired by the Reporting Person in 2015. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:25 UTC |
HENRIQUES RICHARD C JRDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001447028-21-000043 · wf-form4_162309750584527.xml · derivative · entry 1 HENRIQUES RICHARD C JR · CIK 0001181178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-03 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:25 UTC |
BURGESS DANIEL DDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001447028-21-000044 · wf-form4_162309752909256.xml · derivative · entry 1 BURGESS DANIEL D · CIK 0001239650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-03 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:25 UTC |
Meyers James RDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001447028-21-000042 · wf-form4_162309748590209.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-03 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:24 UTC |
MANCHESTER KEITH SDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001447028-21-000041 · wf-form4_162309747011064.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-03 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:24 UTC |
Cheng AndrewDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001447028-21-000040 · wf-form4_162309744639901.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-03 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:24 UTC |
Torti FrankDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001447028-21-000039 · wf-form4_162309743051998.xml · derivative · entry 1 Torti Frank · CIK 0001647805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-03 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 16:57 UTC |
Howard ElizabethChief Compliance Officer
|
GrantStock Options · Derivative | 200,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000008 · wf-form4_161359901972313.xml · derivative · entry 1 Howard Elizabeth · CIK 0001669530 · Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 22:08 UTC |
Picchio GastonChief Development Officer
|
GrantStock Options · Derivative | 250,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000014 · wf-form4_161359969444382.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 22:06 UTC |
HASTINGS DAVID CChief Financial Officer
|
GrantStock Options · Derivative | 250,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000012 · wf-form4_161359955145004.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 21:55 UTC |
McElhaugh Michael J.Chief Business Officer
|
GrantStock Options · Derivative | 249,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000006 · wf-form4_161359884797554.xml · derivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,000 Underlying: Common Stock · 249,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 22:00 UTC |
Collier William H.Director · President and CEO
|
GrantStock Options · Derivative | 675,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000010 · wf-form4_161359921500159.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 21:52 UTC |
Sofia Michael J.Chief Scientific Officer
|
GrantStock Options · Derivative | 290,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000004 · wf-form4_161359869528005.xml · derivative · entry 1 Sofia Michael J. · CIK 0001635324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 22:06 UTC |
McElhaugh Michael J.Chief Business Officer
|
SaleCommon Stock | 20,000 | $5.00 | $100,000.00 |
DisclosureSEC source: 0001447028-21-000002 · wf-form4_161299476323256.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,307,457 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:33 UTC |
McElhaugh Michael J.Chief Business Officer
|
SaleCommon Stock | 10,000 | $5.00 | $50,032.00 |
DisclosureSEC source: 0001447028-20-000152 · wf-form4_160815442050068.xml · nonDerivative · entry 2 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,327,457 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:33 UTC |
McElhaugh Michael J.Chief Business Officer
|
SaleCommon Stock | 30,000 | $5.00 | $150,000.00 |
DisclosureSEC source: 0001447028-20-000152 · wf-form4_160815442050068.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,337,457 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2020. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 20:06 UTC |
Picchio GastonChief Development Officer
|
GrantCommon Stock · Derivative | 50,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000144 · wf-form4_160106438963827.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2020-02-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on February 14, 2020, the trading day immediately preceding the date the performance based option grant wasapproved by the Executive Compensation and Human Resources Committee of the Board of Directors (the "Committee") of Arbutus Biopharma Corporation, subject to both shareholder approval of anamendment to the Registrant's 2016 Omnibus Share and Incentive Plan (the "Plan Amendment") and the fulfillment of certain performance criteria. F2 · derivative.exercise_date: The Registrant's shareholders approved the Plan Amendment on May 28, 2020. On September 23, 2020, the Committee determined that the performance criteria had been met. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 20:05 UTC |
Collier William H.Director · President and CEO
|
GrantStock Options · Derivative | 70,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000143 · wf-form4_160106428541454.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on February 14, 2020, the trading day immediately preceding the date the performance based option grant was approved by the Executive Compensation and Human Resources Committee of the Board of Directors (the "Committee") of Arbutus Biopharma Corporation, subject to both shareholder approval of an amendment to the Registrant's 2016 Omnibus Share and Incentive Plan (the "Plan Amendment") and the fulfillment of certain performance criteria. F2 · derivative.exercise_date: The Registrant's shareholders approved the Plan Amendment on May 28, 2020. On September 23, 2020, the Committee determined that the performance criteria had been met. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:27 UTC |
McElhaugh Michael J.Chief Business Officer
|
SaleCommon Stock | 20,000 | $5.01 | $100,200.00 |
DisclosureSEC source: 0001447028-20-000080 · wf-form4_159588525290974.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367,457 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2020. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:03 UTC |
HENRIQUES RICHARD C JRDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001447028-20-000068 · wf-form4_159104538438792.xml · derivative · entry 1 HENRIQUES RICHARD C JR · CIK 0001181178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-28 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:04 UTC |
Meyers James RDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001447028-20-000069 · wf-form4_159104546646108.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-28 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:01 UTC |
Torti FrankDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001447028-20-000066 · wf-form4_159104524972312.xml · derivative · entry 1 Torti Frank · CIK 0001647805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-28 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:02 UTC |
Collier William H.Director · President and CEO
|
GrantStock Options · Derivative | 262,313 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000067 · wf-form4_159104531419172.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,313 Underlying: Common Stock · 262,313 shares Expires 2030-02-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on February 14, 2020, the trading day immediately preceding the date the option grant was approved by the Executive Compensation and Human Resources Committee of the Board of Directors (the "Committee") of Arbutus Biopharma Corporation, subject to shareholder approval of an amendment to the Registrant's 2016 Omnibus Share and Incentive Plan (the "Plan Amendment"). F2 · date: The option grant was approved by the Committee on February 17, 2020, subject to shareholder approval of the Plan Amendment. The Registrant's shareholders approved the Plan Amendment on May 28, 2020. F3 · derivative.exercise_date: The stock option will vest and become exercisable as to 3/48ths of the common shares on the grant date and an additional 1/48th of the total original common shares on the 17th day of each of the next 45 months. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:58 UTC |
Cheng AndrewDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001447028-20-000065 · wf-form4_159104509367362.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-28 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:57 UTC |
MANCHESTER KEITH SDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001447028-20-000064 · wf-form4_159104502505994.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-28 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:56 UTC |
BURGESS DANIEL DDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001447028-20-000063 · wf-form4_159104495703408.xml · derivative · entry 1 BURGESS DANIEL D · CIK 0001239650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-28 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 08:05 UTC |
Howard ElizabethChief Compliance Officer
|
GrantStock Options · Derivative | 79,500 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000031 · wf-form4_158211751928342.xml · derivative · entry 1 Howard Elizabeth · CIK 0001669530 · Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 13:05 UTC |
Sofia Michael J.Chief Scientific Officer
|
GrantStock Options · Derivative | 250,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000030 · wf-form4_158211749728222.xml · derivative · entry 1 Sofia Michael J. · CIK 0001635324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 13:04 UTC |
Picchio GastonChief Development Officer
|
GrantStock Options · Derivative | 150,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000029 · wf-form4_158211747537119.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 13:04 UTC |
Collier William H.Director · President and CEO
|
GrantStock Options · Derivative | 367,087 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000028 · wf-form4_158211745366536.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,087 Underlying: Common Stock · 367,087 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 13:03 UTC |
HASTINGS DAVID CChief Financial Officer
|
GrantStock Options · Derivative | 100,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000027 · wf-form4_158211739512646.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 13:02 UTC |
McElhaugh Michael J.Chief Business Officer
|
GrantStock Options · Derivative | 200,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000026 · wf-form4_158211733691572.xml · derivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:15 UTC |
HENRIQUES RICHARD C JRDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000051 · wf-form4_156633214408707.xml · derivative · entry 1 HENRIQUES RICHARD C JR · CIK 0001181178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:18 UTC |
Cheng AndrewDirector
|
GrantStock Options · Derivative | 60,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000057 · wf-form4_156633226904329.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. F2 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning one year from the grant date. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:17 UTC |
POTTER MYRTLE SDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000056 · wf-form4_156633224863367.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:17 UTC |
BURGESS DANIEL DDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000054 · wf-form4_156633220629149.xml · derivative · entry 1 BURGESS DANIEL D · CIK 0001239650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:16 UTC |
Meyers James RDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000053 · wf-form4_156633218636070.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:16 UTC |
MANCHESTER KEITH SDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000052 · wf-form4_156633216383352.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. F2 · ownership.direct: Dr. Manchester is the Head of Life Sciences and a Portfolio Manager at QVT Financial LP and serves as a director on behalf of QVT Financial LP and its affiliates. Dr. Manchester holds these stock options for the benefit of certain funds managed by QVT Financial LP. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:15 UTC |
Torti FrankDirector
|
GrantStock Options · Derivative | 22,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000050 · wf-form4_156633212358420.xml · derivative · entry 1 Torti Frank · CIK 0001647805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:18 UTC |
Collier William H.Director · President and CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 1,112,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001123292-19-000911 · edgar.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,000 Underlying: Common Shares · 1,112,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: The stock option will vest and become exercisable as to 25% of the common shares on June 24, 2020 and as to an additional 1/48th of the total original number of common shares subject to Mr. Collier's stock option on the corresponding day of each month over the three year period thereafter, subject to Mr. Collier's continued employment with Arbutus Biopharma Corporation through the applicable vesting dates. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:06 UTC |
Howard ElizabethExecutive VP & General Counsel
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000432 · edgar.xml · derivative · entry 1 Howard Elizabeth · CIK 0001669530 · Executive VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Shares · 137,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:07 UTC |
Murray Mark J.Director · President and CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 357,500 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000435 · edgar.xml · derivative · entry 1 Murray Mark J. · CIK 0001628383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,500 Underlying: Common Shares · 357,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:09 UTC |
Picchio GastonChief Development Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000438 · edgar.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Shares · 137,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:08 UTC |
Sofia Michael J.Chief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000437 · edgar.xml · derivative · entry 1 Sofia Michael J. · CIK 0001635324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Shares · 145,000 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:07 UTC |
McElhaugh Michael J.Chief Business Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 104,500 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000436 · edgar.xml · derivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,500 Underlying: Common Shares · 104,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.